G42 Healthcare signs distribution agreement for Oxford Nanopore Technologies’ sequencing products

70
  • Part of G42 Healthcare’s vision to make UAE a hub of health and life sciences
  • Oxford Nanopore Technologies offers real-time, accurate, accessible, and scalable analysis of DNA and RNA

Abu Dhabi: G42 Healthcare, the Abu Dhabi-based health-tech company, today announced the signing of a distribution agreement with Oxford Nanopore as a channel partner for their DNA/RNA sequencing products across Gulf Co-operation Council (GCC) countries, Jordan, Pakistan, Egypt, and Iraq.

Oxford Nanopore’s sequencing devices include the MinION, GridION, PromethION, VolTRAX and Flongle. This agreement is aligned with G42 Healthcare’s vision to make UAE the regional hub of health and life sciences by offering technology for real-time, accurate, accessible, and scalable analysis of DNA and RNA. The technology supports scientific analyses to further understand the biology of humans, bacteria, viruses, and environments as well as to understand diseases such as cancer.

With this channel partnership, G42 Healthcare aims to build on its current sequencing capabilities by offering Oxford Nanopore’s sequencing technology, which offers a range of market-disrupting features. This includes the ability to sequence any length of DNA/RNA fragments, from short to ultra-long, thereby offering richer genomic insights; the ability to stream data in real-time for rapid insights; the ability to sequence native DNA/RNA strands to elucidate richer information including real-time methylation data. A range of analyses from whole genome assembly to targeted sequencing or metagenomic analysis can be performed.

In addition to distribution of the technology, G42 Healthcare has the option to provide sequencing services internationally, with the potential to offer sequencing of human and non-human samples to a range of customers including governments, research institutes, hospitals, and omics centres in the GCC and beyond. With a deep focus on offering sequencing as a service, G42 Healthcare has the potential to provide broad, high-impact, rapid insights to enable the interpretation of accurate, rich biological data at scale, by leveraging nanopore sequencing technology.

Talking about the distribution agreement with Oxford Nanopore, Ashish Koshy, CEO of G42 Healthcare, said: “G42 Healthcare has leveraged nanopore sequencing to facilitate the world’s most comprehensive population genomics initiative in the UAE, and therefore, has a deep understanding of how to deliver at scale, from sample management to advanced analytics. In line with this, our agreement with Oxford Nanopore assumes great significance as it will help us achieve real-time, high-performance, accessible, and scalable analysis of DNA and RNA, to support rapid clinical research and outbreak surveillance. We are excited about potential future developments that could include providing high-impact testing with nanopore sequencing.”

 “G42 Healthcare will leverage its experience to support projects across GCC and penetrate new markets across the region. As an end-to-end service provider, we can support with long and short-read sequencing requirements regardless of location, capabilities, and infrastructure of governments, healthcare providers, and research institutes. This agreement is a strategic step forward to realising our vision to develop a world-class healthcare sector in the UAE,” added Koshy.

Gordon Sanghera, CEO of Oxford Nanopore Technologies, said: “Our technology delivers accurate, comprehensive genomic data, in real-time and in formats that can scale from pocket size to ultra-high output. We have developed a new generation of sensing technology that uses nanopore – nano-scale holes – embedded in high-tech electronics to perform precise molecular analyses. We are excited to collaborate closely with G42 Healthcare in furthering our vision of analysing anything, by anyone and anywhere.”

Oxford Nanopore’s technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments.

Earlier this year, Biogenix Labs – part of G42 Healthcare, became the first laboratory in the Middle East to conduct sequencing for COVID-19 surveillance and variant detection using Oxford Nanopore’s technology. With that, Biogenix Labs became the first lab in the Middle East to be certified for cost-effective, high-accuracy sequencing for genomic epidemiology for COVID-19 strain surveillance.

About G42 Healthcare

G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalized and preventive care and transforming the traditional healthcare ecosystem. We have built Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, facilitated the 4Humanity clinical trials, the world’s first phase three trial for inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities across the pan-Arab region, established the region’s first dedicated contract research organization (IROS) for conducting clinical research with and for local populations, supported UAE’s healthcare authorities on the national vaccination implementation, conducted research into new vaccines and drug therapies, and built Omics Centre of Excellence, the region’s largest and most technologically advanced Omics facility that is the backbone for the Emirati Genome Program, the world’s most comprehensive population genomics initiative.